Navigation Links
Inspiration Biopharmaceuticals Presents Data From Hemophilia,Program at International Society On Thrombosis and Haemostasis,(ISTH) Annual Meeting

GENEVA, July 11, 2007 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of preclinical data supporting the development of new, proprietary forms of recombinant Factor IX to treat patients with Hemophilia B. The data were highlighted in an oral presentation and a poster session at the XXIst Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland.

Dougald M. Monroe, Ph.D., Associate Professor, UNC School of Medicine, University of North Carolina at Chapel Hill, gave an oral presentation titled, "Glycosylation of the Activation Peptide of Factor IX Determines Plasma Half Life." Michael Griffith, Ph.D., President and CEO of Inspiration Biopharmaceuticals, presented a poster titled, "N-Glycan Sialylation is Important for In Vivo Recovery of Recombinant Factor IX." According to both presentations, Inspiration has identified structural properties of Factor IX that may improve the half-life and recovery compared to commercially available recombinant Factor IX. The company is currently refining its cGMP manufacturing process to maximize the biological properties of its clinical product based on these studies.

"Inspiration Biopharmaceuticals is seeking to revolutionize the treatment of hemophilia by providing high quality, less costly Factor products. Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "We are therefore excited about the progress that we have made in advancing our protein manufacturing technology. We look forward to initiating clinical trials this year."

About Recombinant Protein Manufacturing Technology

Inspiration Biopharmaceuticals uses novel patent protected, recombinant protein manufacturing technologies which are demonstrated to s
'"/>




Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
4. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session

Post Your Comments:
(Date:11/19/2009)... Nov. 19 The D e al ... its Most Admired Corporate Dealmakers for the sec...s its Most Admired Dealmaker in pharma/biotech for...and divestitures since January 2006. ,, Over th...rtfolio with a focus on high-growth, innovation-dr...
(Date:11/19/2009)... Nov. 19 Mach 7 Technologies, a ...re image management solutions, and QStar Technolog... PACS- neutral archive solution through their comm...international leader in providing digital image di...industry. Under the agreement, Data Distributing ...
(Date:11/19/2009)...tors, Endocrinologists Feel Ill-Equipped to Provid...ETON, N.J., Nov. 19 Nearly one-thi...gh time and did not receive sufficient reimburseme... with diabetes, according to the results of a stud...lished today in American Health & Drug Benefi...
Breaking Medicine Technology:The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 2Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 4Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 2Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 3Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 4Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 5Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call 13296 1Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call 13296 2Cancer Survivors Face Tough Road Long After Treatment Ends 53273 1Cancer Survivors Face Tough Road Long After Treatment Ends 53273 2Cancer Survivors Face Tough Road Long After Treatment Ends 53273 3Tevas Forum Draws Key Pennsylvania Healthcare Leaders 53270 1Tevas Forum Draws Key Pennsylvania Healthcare Leaders 53270 2
...Health Organizations Unite to Help Educate on Good... Other Serious,Health Problems, SEATTLE, April 10,...ooking at the prevalence and cost of type 2 diabet... of five people,(57.9 percent) with type 2 diabete...oblems commonly associated with the disease, and,t...
...Md., April 10, 2007 /PRNewswire-FirstCall/ -- Aval...N944 will be the,subject of three poster presentat...ch 2007 Annual Meeting to be held on April 14-18,...sented by Avalon, will review the data,derived fro...944,for the treatment of hematological cancers. Th...
Other Medicine Technology:First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7Avalon Pharmaceuticals to Present at the American Association for,Cancer Research 2007 Annual Meeting 2Avalon Pharmaceuticals to Present at the American Association for,Cancer Research 2007 Annual Meeting 3Avalon Pharmaceuticals to Present at the American Association for,Cancer Research 2007 Annual Meeting 4
(Date:11/20/2009)... , NEW YORK, Nov. 20 Reportl...ort is available in its catalogue. ,, Oncology...ecast to 2013 ,, http://www.reportlinker.com...ks-and-Market-Forecast-to-2013.html#utm_source=prn...ire ,, Comprehensive Forecasts and Detailed B...
(Date:11/20/2009)... , NEW YORK, Nov. 20 Reportl...ort is available in its catalogue. ,, Imaging .../www.reportlinker.com/p0164325/Imaging-Agents---A-...&utm_medium=pr&utm_campaign=prnewswire ,... the visualization of organs within the human body...
(Date:11/20/2009)..., HINESBURG, Vt., Nov. 20 Kestre... that specializes in creating sophisticated medica...nounced the launch www.infectioncontrolsource.com...administrators with a comprehensive database of in...ur mission at Kestrel is to educate healthcare adm...
(Date:11/20/2009)... , LOS ANGELES, Nov. 20 As we a...asts, more than 1.25 million people in Los Angeles...d the magnitude of the problem, that,s nearly the ...ple you see every day are hungry - and the situati...nues to increase. ,, The Jewish Federation of ...
(Date:11/20/2009)...ecule identified by researchers , , FRI...e moving closer to better treatments for bovine sp...isease, and the related condition called Creutzfel... is crucial to the development of mad cow disease,...nding its role could help scientists figure out ho...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013 2Health News:Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013 3Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 2Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 3Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 4Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 5Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 6Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 7Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 8Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 9Health News:Infection Prevention Online Community Site Launches - Focused on Product Selection 2Health News:The Jewish Federation Unveils Blueprint to End Hunger in Los Angeles 2Health News:The Jewish Federation Unveils Blueprint to End Hunger in Los Angeles 3
...to get him involved in wrestling early, and it may...udy reveals the levels of all groups of white bloo...iller cells, in boys ages 14 to 18 after a one-and...ystem responsiveness before and after the wrestlin...
...archers say evidence does not suggest any increase...omen who have had a spontaneous or induced abortio...reast cancer was .98 for women whose pregnancies e...t on the subsequent risk of breast cancer. The num...
...s are allergic to fish and shellfish and self-repo...gy’ // to seafood is reported by 2.3 percent of th...mericans.” In a recent study researchers found...rmine the prevalence of self-reported seafood alle...
...is just as harmful to kids as is smoking during pr...smoke exposure in the womb and after birth increas... 10 years.Researchers studied the effect of smoke ...udied what effect tobacco exposure had on children...
... an adhesive patch that resembles the size of a cr...ver pain medication through the skin does the job ... // The patch is affixed to the patient's upper ar... company-funded study. Manufacturers say the...
...ed States have an impaired or absent sense of smel... trauma, viral infection, nasal obstruction, septa...hormonal disturbances, or normal aging can cause c...ired or absent sense of smell every day. New resea...
Other Medicine News:
Cartesian Pipettor
WellPro Automated Liquid Handler tm Short Base
Wellpro 384
...rep series of robotic workstations is designed for... the ideal automation platform for routine sample ...ry procedures, improving throughput, process consi...niPrep software allows you to control the robotic ...
Medicine Products: